BackNovo Nordisk A/S Class B Overview

Novo Nordisk A/S Class B Receivables

Novo Nordisk A/S Class B's receivables is $110B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$108.51B
26.41% YoYΔ $22.67B vs prior year quarter

Peer trimmed avg / median

Loading

Novo Nordisk A/S Class B Receivables History

Loading

Novo Nordisk A/S Class B vs. peers: Receivables Comparison

Loading

Novo Nordisk A/S Class B Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Novo Nordisk A/S Class B (NONOF) FAQ

As of the most recent data (June 2026), NONOF shows a receivables of $110B. That compares with $86B in the prior-year period — up 26.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's receivables is now $110B (was $86B) — a 26.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

Tracking NONOF's receivables over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $110B That compares with $86B in the prior-year period — up 26.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $110B) with ownership activity and broader fundamentals.

Novo Nordisk A/S Class B's receivables is $110B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.